IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138 [Yahoo! Finance]
TransCode Therapeutics, Inc. (RNAZ)
Company Research
Source: Yahoo! Finance
LOS ANGELES, CA - May 1, 2025 ( NEWMEDIAWIRE TransCode Therapeutics (NASDAQ: RNAZ) reported continued progress in its Phase 1a trial of TTX-MC138, an RNA-based therapeutic targeting microRNA-10b in metastatic cancer. Thirteen patients have received at least one dose across four dosing levels, with no significant toxicities observed. Eight patients remain in the trial, with two showing stable disease after seven months. Early PK/PD data indicate target engagement and a dose-response relationship consistent with preclinical findings. The results support advancing the trial to Phase 1b for expanded safety and anti-tumor activity evaluation. To view the full press release, visit https://ibn.fm/OjVf3 About TransCode Therapeutics TransCode is a clinical-stage oncology company focused on treating metastatic disease. The Company is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform.
Show less
Read more
Impact Snapshot
Event Time:
RNAZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RNAZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RNAZ alerts
High impacting TransCode Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RNAZ
News
- TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors [Yahoo! Finance]Yahoo! Finance
- TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of DirectorsPR Newswire
- TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trialPR Newswire
- TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer [Yahoo! Finance]Yahoo! Finance
- TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development OfficerPR Newswire
RNAZ
Sec Filings
- 12/23/25 - Form DEFA14A
- 12/23/25 - Form 8-K/A
- 12/23/25 - Form EFFECT
- RNAZ's page on the SEC website